NKG2A‐checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA‐E

NKG2A has emerged as a new immunotherapy target and its blockade with the novel immune checkpoint inhibitor (ICI) monalizumab can boost both NK cell and CD8(+) T cell responses. NKG2A forms heterodimers with CD94 and binds to the human non‐classical MHC class I molecule HLA‐E. HLA‐E forms complexes...

Descripción completa

Detalles Bibliográficos
Autores principales: Battin, Claire, Kaufmann, Gabriel, Leitner, Judith, Tobias, Joshua, Wiedermann, Ursula, Rölle, Alexander, Meyer, Marten, Momburg, Frank, Steinberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426624/
https://www.ncbi.nlm.nih.gov/pubmed/35596615
http://dx.doi.org/10.1111/imm.13515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426624/
https://www.ncbi.nlm.nih.gov/pubmed/35596615
http://dx.doi.org/10.1111/imm.13515

Ejemplares similares